INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Nomethiazoles: PK/PD Study of a Novel Class of Alzheimer’s Disease Therapeutics

Show full item record

Bookmark or cite this item:

Files in this item

File Description Format
PDF Tavassoli_Ehsan.pdf (2MB) (no description provided) PDF
Title: Nomethiazoles: PK/PD Study of a Novel Class of Alzheimer’s Disease Therapeutics
Author(s): Tavassoli, Ehsan
Advisor(s): Thatcher, Gregory R.
Department / Program: Medicinal Chemistry and pharmacognosy
Graduate Major: Medicinal Chemistry
Degree Granting Institution: University of Illinois at Chicago
Degree: MS, Master of Science
Genre: Masters
Subject(s): Nomethiazoles Alzheimer's NO mimetics Cognition NO chimera Clomethiazole anti AD drugs GABA potentiator
Abstract: Since Alzheimer’s disease (AD) is a complex disease, multi-target drugs appear to be more promising in AD therapy than those targeting just one possible underlying mechanism of the disease. Therefore, a new class of hybrid molecules (Nomethiazoles) was introduced based on the role of nitric oxide in memory and neuroprotection in addition to the anti-inflammatory and neuroprotective properties of clomethiazole (CMZ). Nomethiazoles were developed through coupling of a nitrate group with the methylthiazole pharmacophore of the neuroprotectant CMZ. GT-1061, a prototype of nomethiazoles, was proved to be active in different animal models of cognition and neuroprotection, which paved the way to enter clinical trials. The major goal of this study was to evaluate the procognitive properties of two types of recently designed nomethiazoles, diaryl and triazole compounds, in step-through passive avoidance assay, a model for cognition deficit. In mice, all the novel nomethiazoles were active in reversing the cognition deficit induced by scopolamine and L-NAME (NOS inhibitor). The diaryl compounds maintained their potency longer than the triazoles. Based on the hypothesized involvement of GABA potentiation by nomethiazole, sedation was measured by accelerated rotarod performance task and compared with CMZ and GT-1061. The novel nomethiazoles were less sedative than CMZ at equimolar doses. LC-MS/MS was used to evaluate the blood brain barrier permeability of nomethiazoles. Consequently, diaryl compounds were shown to produce a higher brain plasma concentration ratio than triazole compounds. The OH metabolites formed from nomethiazoles were also detected in mice brain samples and were correlated with the sedative activity of these hybrid molecules. The study not only proved the brain bioavailability of novel nomethiazoles, but also demonstrated their procognitive action accompanied with less sedative activity when compared with CMZ and GT-1061
Issue Date: 2012-12-10
Genre: thesis
Rights Information: Copyright 2012 Ehsan Tavassoli. All the related results taken from the pharmacokinetics and pharmacological studies should be discussed with the author before any publication.
Date Available in INDIGO: 2012-12-10
Date Deposited: 2012-05

This item appears in the following Collection(s)

Show full item record


Country Code Views
United States of America 132
China 39
United Kingdom 7
Australia 2
Netherlands 2


My Account


Access Key